Septodont, the dominant global leader in dental anesthetics, has made a strategic investment in Balanced Pharma Inc. (“BPI”) as part of an institutional funding round, and Septodont COO Atif Zia has joined the BPI board of directors.
Balanced Pharma aims to commercialize multiple new, best-in-class drugs and provide significant increases in patient comfort and safety during and after many common procedures. Goals include multi-day pain relief and reduced opioid use following orthopedic and oral surgery, as well as faster, less painful, and more reliable local anesthesia for dental procedures.
Balanced Pharma has raised approximately $6.5 million of its current $8 million funding round. When closed, this round will bring total investment in BPI to approximately $12 million, including more than $9 million from dentists and dental industry insiders.
“We are very proud to add Septodont to the growing list of dental industry members who are investing in the development of these important products and to have Atif as part of our leadership team,” says Dr. Scott Keadle, a former dentist and Balanced Pharma CEO.
BPI-001 and BPI-002, Balanced Pharma’s flagship drugs for dentistry, are reformulated versions of the injectable local anesthetics lidocaine and articaine. Both drugs will feature improved salt and acid balance, targeting less pain, faster onset, and superior reliability. Notably, both drugs will continue to be provided in a standard dental cartridge, ensuring a seamless replacement for current products without the need for additional devices or changes in clinical protocol. Balanced Pharma intends to bring BPI-001 to the U.S. market in Q4 2027, followed by BPI-002 and expansion into global markets. Balanced Pharma believes that BPI-001 and BPI-002 will compete favorably against incumbent drugs in an estimated $2.9 billion annual retail market.
BPI-004 is an injectable non-opioid analgesic combining tetracaine 0.2%, lidocaine 0.4%, and epinephrine 1:250,000. When injected during surgery, BPI-004 will target up to three days of analgesia with low toxicity, minimal motor impairment, and reduced opioid use. Balanced Pharma is exploring plans to bring BPI-004 to the U.S. market as early as Q2 2025 under a 503(b) exemption.
Balanced Pharma believes that BPI-004 will compete favorably against incumbent drugs bupivacaine and liposomal bupivacaine in the estimated $9 billion annual U.S. retail market.
BPI’s proprietary technology platform was designed by a dentist to enable new injectable anesthetic and analgesic drugs for use in multiple indications, including orthopedic surgery, general surgery, oral surgery, and general dentistry.
About Balanced Pharma
More information about Balanced Pharma can be found on the company’s website at balancedpharma.com.
All BPI products are currently in development, have not been approved by the FDA, and are not available for marketing or sale in the United States.
About Septodont
More information about Septodont can be found on the company’s website at septodontcorp.com.
